Grupo para la caracterización molecular de las neoplasias hematológicas
Instituto de Investigación Sanitaria de Navarra
Pamplona, EspañaPublications en collaboration avec des chercheurs de Instituto de Investigación Sanitaria de Navarra (4)
2023
-
Biallelic TET2 mutations confer sensitivity to 5′-azacitidine in acute myeloid leukemia
JCI Insight, Vol. 8, Núm. 2
-
Correction: Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY (Leukemia, (2023), 37, 2, (339-347), 10.1038/s41375-022-01802-y)
Leukemia
-
Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY
Leukemia, Vol. 37, Núm. 2, pp. 339-347
2021
-
Measurable residual disease in elderly acute myeloid leukemia: Results from the PETHEMA-FLUGAZA phase 3 clinical trial
Blood Advances, Vol. 5, Núm. 3, pp. 760-770